Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
The Effect of Spironolactone on Pain in Older People With Osteoarthritis
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 86
- Registration Number
- NCT02046668
- Locations
- 🇬🇧
NHS Fife, Kirkcaldy, Fife, United Kingdom
🇬🇧NHS Tayside, Dundee, Tayside, United Kingdom
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
- Conditions
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Peter Rossing
- Target Recruit Count
- 1777
- Registration Number
- NCT02040441
- Locations
- 🇨🇿
Institut Klinické a Experimentální Mediciny, Prague, Czechia
🇩🇰Steno Diabets Center Copenhagen, Gentofte, Denmark
🇨🇿Universita Karlova v Praze, Prague, Czechia
Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01944384
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 41
- Registration Number
- NCT01897727
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 19
- Registration Number
- NCT01867294
- Locations
- 🇺🇸
Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States
🇺🇸Marshfield Clinic, Marshfield, Wisconsin, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
- Conditions
- Interventions
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Brigham and Women's Hospital
- Registration Number
- NCT01855334
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 61
- Registration Number
- NCT01853553
- Locations
- 🇺🇸
UColorado, Aurora, Colorado, United States
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
- Conditions
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 823
- Registration Number
- NCT01848639
- Locations
- 🇫🇷
Clinique Bouchard, Marseille, France
🇫🇷CHU Caen, Caen, France
🇫🇷CH Avignon, Avignon, France
A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01821703
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zuidlaren, Netherlands
Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- West Virginia University Healthcare
- Target Recruit Count
- 40
- Registration Number
- NCT01721655
- Locations
- 🇺🇸
West Virginia University Healthcare, Morgantown, West Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.